Universe Pharmaceuticals (UPC) Enterprise Value (2020 - 2025)

Universe Pharmaceuticals has disclosed Enterprise Value across 6 years of filings, most recently posting -$70.2 million for Q3 2025.

• Enterprise Value for Q3 2025 came in at -$70.2 million, up 99.77% year-over-year; the trailing twelve-month figure through Sep 2025 was -$70.2 million (up 99.77% YoY), and the FY2025 annual result was -$70.2 million, up 99.77% from the prior year.
• Enterprise Value came in at -$70.2 million for Q3 2025 at Universe Pharmaceuticals, up from -$30.9 billion in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$11.4 million in Q1 2024 to a low of -$30.9 billion in Q3 2024.
• The 5-year median for Enterprise Value is -$49.4 million (2022), against an average of -$5.3 billion.
• Across the five-year window, Enterprise Value plunged 26155.92% in 2022 and surged 99.77% in 2025, its largest moves.
• Universe Pharmaceuticals' Enterprise Value stood at -$21.8 million in 2021, then slumped by 26155.92% to -$5.7 billion in 2022, then advanced by 7.65% to -$5.3 billion in 2023, then slumped by 484.03% to -$30.9 billion in 2024, then soared by 99.77% to -$70.2 million in 2025.
• The last three Enterprise Value figures came in at -$70.2 million (Q3 2025), -$30.9 billion (Q3 2024), and -$11.4 million (Q1 2024), per Business Quant data.